Parabilis Medicines Inc.

Last updated September 27, 2026

Organization details

Legal name
Parabilis Medicines Inc.
Former names
FOG Pharmaceuticals, INC.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Cambridge
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
PBLS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001657677
EIN
47-4505725

Board of directors

Chief executives

Mathai Mammen · President & CEO
Since June 2026

Board connections

9 of this board's directors also sit on 33 other boards. 32 are in the same sector.

Network of Parabilis Medicines Inc.'s board connections Bicara Therapeutics Inc. Bicara Therapeutics In... Janux Therapeutics Inc. Janux Therapeutics Inc... Septerna Inc. Septerna Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bambusa Therapeutics Inc. Bambusa Therapeutics I... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. Jake Simson Jake Simson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Parabilis Medicines Inc.
Shared director Other board Same sector +17 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$441,418,109
14 purchases by 4 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jul 22, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +47,250 $29.77 $1,406,633
Jul 21, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +21,696 $27.96 $606,620
Jul 21, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +6,504 $29.17 $189,722
Jul 21, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +37,723 $30.00 $1,131,690
Jul 20, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +98,433 $27.13 $2,670,487
Jul 20, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +32,987 $27.72 $914,400
Jun 15, 2026 Alan Sebulsky Director Open-market purchase +5,000 $26.00 $130,000
Jun 15, 2026 Alan Sebulsky Director Open-market purchase +4,065 $27.10 $110,162
Jun 12, 2026 Alan Sebulsky Director Open-market purchase +8,435 $27.67 $233,396
Jun 11, 2026 Soleus Capital Group, LLC 10% owner Open-market purchase +375,000 $20.00 $7,500,000
Jun 11, 2026 RA Capital Nexus Fund III, L.P. Director Derivative conversion +6,556,740 — —
Jun 11, 2026 Edward M. Fitzgerald Director Derivative conversion +5,539 — —
Jun 11, 2026 Alan Sebulsky Director Open-market purchase +12,500 $20.00 $250,000
Jun 11, 2026 Alexis Borisy Director Derivative conversion +105,414 — —
Jun 11, 2026 Deerfield Mgmt HIF, L.P. 10% owner, Possible Member of 10% Group Derivative conversion +122,990 — —

Organizations in the same sector, closest in location and size first.

Questions about Parabilis Medicines Inc.

Who is the CEO of Parabilis Medicines Inc.?

Mathai Mammen has been Parabilis Medicines Inc.'s President & CEO since June 2026.

How many directors are on Parabilis Medicines Inc.'s board?

Parabilis Medicines Inc.'s board has 11 directors: Alan Sebulsky, Alexis Borisy, Barbara Weber, Craig Tendler, Edward M. Fitzgerald, Jake Simson, Krishna Yeshwant, Mathai Mammen, Peter Kolchinsky, Rajeev M. Shah and 1 other.

Are Parabilis Medicines Inc. insiders buying or selling shares?

Over the last 12 months, Parabilis Medicines Inc. insiders bought $441.4 million of shares in 14 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="parabilis-medicines-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.